[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625692":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":45,"centralContacts":49,"locations":54,"responsibleParty":69,"collaborators":32,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":32,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":32,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":57,"whyStopped":32,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Electronic Science and Technology of China","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo and oxytocin group","EXPERIMENTAL","Subjects receive placebo of vasoconstrictor and oxytocin treatment",[13,14],"Drug: placebo (compared to vasoconstrictor)","Drug: oxytocin",{"label":16,"type":10,"description":17,"interventionNames":18},"Vasoconstrictor and oxytocin group","Subjects receive vasoconstrictor and oxytocin treatment",[19,14],"Drug: vasoconstrictor (Otrivin)",{"label":21,"type":22,"description":23,"interventionNames":24},"Vasoconstrictor and placebo group","PLACEBO_COMPARATOR","Subjects receive vasoconstrictor and placebo of oxytocin treatment",[19,25],"Drug: placebo (compared to oxytocin)",[27,33,37,41],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","placebo (compared to vasoconstrictor)","intranasal administration of placebo (4 sprays of 0.9% saline and glycerin)",[9],null,{"type":28,"name":34,"description":35,"armGroupLabels":36,"otherNames":32},"vasoconstrictor (Otrivin)","intranasal administration of vasoconstrictor (4 sprays of 0.9% Otrivin)",[16,21],{"type":28,"name":38,"description":39,"armGroupLabels":40,"otherNames":32},"placebo (compared to oxytocin)","intranasal administration of placebo (24 IU)",[21],{"type":28,"name":42,"description":43,"armGroupLabels":44,"otherNames":32},"oxytocin","intranasal administration of oxytocin (24IU)",[9,16],[46],{"name":47,"affiliation":5,"role":48},"Shuxia Yao, Dr","PRINCIPAL_INVESTIGATOR",[50],{"name":47,"role":51,"phone":52,"phoneExt":32,"email":53},"CONTACT","+86 18111297596","yaoshuxia@uestc.edu.cn",[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":32},"University of Electronic Science and Technology of China (UESTC)","RECRUITING","Chengdu","Sichuan","611731","China","CN",{"type":64,"coordinates":65},"Point",[66,67],104.06667,30.66667,{"lat":67,"lon":66},{"type":48,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Shuxia Yao","Associate Professor","100625692","oxytocins-effects-on-emotional-processing-and-its-acting-routes-100625692",false,"NCT07425938","Oxytocin's Effects on Emotional Processing and Its Acting Routes","The Modulatory Effects of Oxytocin on Emotional Processing and Its Acting Routes","Inclusion Criteria:\n\n* Healthy subjects without past or current psychiatric or neurological disorders\n\nExclusion Criteria:\n\n* History of head injury.\n* Medical or psychiatric illness.\n* Subjects take a certain drug for a long period of time.\n* Subjects have metal implants in their bodies.",true,"MALE","18 Years","30 Years",{"count":84,"type":85},120,"ESTIMATED","INTERVENTIONAL",[88],"NA","The main goal of this study is to investigate the modulatory effects of intranasally administrated oxytocin on the processing of emotional stimuli and its acting routes.",[91],"Healthy Adult Male",[42,93,94],"negative emotion","vasoconstrictor","2026-02-20",{"date":97,"type":98},"2026-02-23","ACTUAL",{"date":100,"type":98},"2026-01-24",{"date":102,"type":85},"2026-04-15",{"name":5,"class":6},1]